PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 1, 2026CancersOpen Access

A Biomarker Panel for the Detection of Pancreatic Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYuefan WangYHYuanyu HuangTLTung-Shing M. Lih

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates a three-marker panel for detecting pancreatic cancer, suggesting improved diagnosis.

Key Points

  • This study aims to improve the early detection of pancreatic cancer using a novel biomarker panel.
  • Analyzed serum and plasma samples from 649 participants, including 250 PDAC cases and 399 controls.
  • Employed a three-marker model incorporating serum CA19-9, plasma ITIH3, and CEACAM1.
  • Utilized radial-based SVM with 10-fold cross-validation for model training and independent blinded validation.
  • Achieved an AUC of 0.917 in blinded validation indicating strong performance against controls.
  • The three-marker panel showed a specificity of 53.3% (95% CI: 46.8–59.7%), outperforming CA19-9 alone at 14.5% (95% CI: 10.4–19.7%).
  • Maintained 95% sensitivity while significantly enhancing diagnostics for pancreatic ductal adenocarcinoma.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69f442d4967e944ac5566487https://doi.org/10.3390/cancers18091397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development of a multi-analyte blood test for the early detection of pancreatic ductal adenocarcinoma (PDAC) and performance compared to CA19-9.2024
  2. 2A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity Over CA19-9 Alone2024 · 2 citations
  3. 3Plasma Proteomic Profiling Identifies Candidate Biomarkers for Pancreatic Ductal Adenocarcinoma2026
  4. 4Abstract B027: A blood-based, multiplex protein biomarker signature shows superior performance in detection of early-stage pancreatic ductal adenocarcinoma (PDAC)2024
  5. 5Abstract B063: Immune cell expression-based multi-biomarker blood panel for early detection of pancreatic ductal adenocarcinoma2025